ODD Stock Recent News

Oddity Tech disrupts the beauty industry by leveraging AI and data to enhance online shopping, boasting high consumer satisfaction and repeat purchase rates. The company's DTC model and in-house marketing provide control over brand image and inventory, ensuring sustainable growth and high ROAS. Management's commitment to a 20% growth algorithm and integrity in pacing growth demonstrate long-term vision and strategic planning.

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (“ODDITY”) (NASDAQ: ODD), today announced that it will release its fourth quarter and full year 2024 financial results after the market close on Tuesday, February 25, 2025, to be followed by a conference call on Wednesday, February 26, 2025, at 8:30 a.m. Eastern Time.

Oddity Tech (ODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- On January 31, 2025, ODDITY Tech Ltd. (NASDAQ: ODD, the “Company”) entered into agreements with a syndicate of banks to secure credit facilities for a total of $200 million (collectively the “Facility”). The Facility replaces the Company's previous $100 million credit facility and increases financial flexibility to fund growth initiatives, acquisitions, share buybacks, and other general corporate needs.

ODD is disrupting the legacy beauty and wellness market with technologies like AI, machine learning, data science and computer vision.

ODD, ROAD, and NCNO it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 6, 2024.

Investors can boost returns by adding these top-ranked liquid stocks, DXP Enterprises, Ubiquiti, Sezzle and Oddity Tech, to their portfolios.

Top IPO stocks Astera and Reddit hit new highs this week. Birkenstock is near a buy point.

Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease

Oddity Tech's data-driven, AI-powered DTC model looks set to facilitate market share gains through FY28. ODD's forward EV/EBITDA valuation of 16.2x is pricier than the industry average, but we feel it is worth this premium, considering the superior EBITDA profile of the business. ODD's robust balance sheet, zero debt, and strong free cash flow support have prompted a shift towards share buyback momentum with another $100m yet to be deployed.